Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
LGVN
LGVN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
LGVN News
Avaí Bio Advances Cell Therapy for Aging
Apr 10 2026
PRnewswire
Avaí Bio and Austrianova Advance Anti-Aging Therapy Collaboration
Apr 10 2026
Newsfilter
Longeveron Secures Patent for Potency Assay Methods in China
Apr 08 2026
Newsfilter
LONGEVERON RECEIVES CHINESE PATENT FOR METHODS TO ASSESS POTENCY OF HUMAN MESENCHYMAL STEM CELLS (MSCS)
Apr 08 2026
moomoo
Avaí Bio Initiates Production of α-Klotho Cell Bank
Mar 18 2026
Globenewswire
Avaí Bio Initiates Production of α-Klotho Cells
Mar 18 2026
PRnewswire
Avaí Bio Initiates α-Klotho Cell Production
Mar 18 2026
Newsfilter
Longeveron (LGVN) Q4 2025 Earnings Call Transcript
Mar 18 2026
NASDAQ.COM
Longeveron Reports FY EPS Beat but Increased Losses
Mar 17 2026
seekingalpha
Longeveron Raises $15M to Advance Laromestrocel Therapy
Mar 10 2026
Benzinga
Avaí Bio Advances Cell Therapy Production Milestone
Mar 03 2026
PRnewswire
Avaí Bio Advances α-Klotho Cell Production Milestone
Mar 03 2026
Newsfilter
Longeveron Inc. Reports Positive Trial Results for Age-Related Therapy
Feb 25 2026
stocktwits
Longeveron Reports Positive Phase 2b Clinical Trial Results
Feb 25 2026
Newsfilter
Longeveron Appoints New CEO Stephen H. Willard
Feb 13 2026
seekingalpha
Longeveron Appoints New CEO to Drive Growth
Feb 13 2026
Newsfilter
Show More News
